Matches in DBpedia 2016-04 for { ?s ?p "Cubist Pharmaceuticals is a U.S. biopharmaceutical company with activities spanning from research and development to commercialization of pharmaceutical products. Its main products target pathogens like MRSA.Cubist is one of the few firms that have continued to research in antibiotics while larger pharmaceutical companies have abandoned such research. The company employs 638 people, with 370 in their headquarters in Lexington, MA. As of 2011, the company’s headquarters are under expansion and is expected to occupy 373,000 sq ft (34,700 m2) in Lexington, MA. On 8 December 2014, Merck & Co. acquired Cubist for $102 per share in cash (US$8.4BN) as entree to the market for drugs that can combat superbugs."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Cubist_Pharmaceuticals abstract "Cubist Pharmaceuticals is a U.S. biopharmaceutical company with activities spanning from research and development to commercialization of pharmaceutical products. Its main products target pathogens like MRSA.Cubist is one of the few firms that have continued to research in antibiotics while larger pharmaceutical companies have abandoned such research. The company employs 638 people, with 370 in their headquarters in Lexington, MA. As of 2011, the company’s headquarters are under expansion and is expected to occupy 373,000 sq ft (34,700 m2) in Lexington, MA. On 8 December 2014, Merck & Co. acquired Cubist for $102 per share in cash (US$8.4BN) as entree to the market for drugs that can combat superbugs.".
- Q5192265 abstract "Cubist Pharmaceuticals is a U.S. biopharmaceutical company with activities spanning from research and development to commercialization of pharmaceutical products. Its main products target pathogens like MRSA.Cubist is one of the few firms that have continued to research in antibiotics while larger pharmaceutical companies have abandoned such research. The company employs 638 people, with 370 in their headquarters in Lexington, MA. As of 2011, the company’s headquarters are under expansion and is expected to occupy 373,000 sq ft (34,700 m2) in Lexington, MA. On 8 December 2014, Merck & Co. acquired Cubist for $102 per share in cash (US$8.4BN) as entree to the market for drugs that can combat superbugs.".